Elekta signs partnership agreement with RTsafe for delivery of safe and efficient stereotactic cancer treatments

STOCKHOLM, March 21, 2019 – Elekta (EKTA-B.ST) and RTsafe today announced that they have entered into an agreement under which Elekta will be the distributor of innovative, 3D printed PseudoPatient™ phantoms and remote dosimetry services.

Linac-based stereotactic radiosurgery/radiotherapy (SRS/SRT) offers significant benefits to patients and Elekta has the best tools to deliver these extremely precise treatments. As the demand for stereotactic treatments increases, so does the customer’s appetite for high-end solutions to provide those treatments. RTsafe simplifies the implementation of very complex therapeutic treatment techniques with its solution.

RTsafe’s approach is an important advancement for enabling effective quality assurance (QA) across the complete SRS/SRT continuum using Elekta’s Versa HD™ systems with High definition dynamic radiosurgery (HDRS). This is particularly important for high-dose, highly focused stereotactic techniques that demand extreme accuracy in all phases of treatment delivery, from patient set up to image guidance and radiation delivery to the patient. The absence of an end-to-end stereotactic confidence service has been a key barrier to broader adoption and clinical implementation of SRS and SRT, despite the clear benefits that these approaches can provide to patients with a variety of cranial indications, including brain metastases.

“Elekta’s partnership with RTsafe is another example of our strategy to facilitate and accelerate the implementation of accurate QA processes that enable a broad array of customers to safely deploy High-definition dynamic radiosurgery (HDRS),” said Maurits Wolleswinkel, Head of Portfolio and Chief Strategy Officer at Elekta. “High-dose, linac-based SRS and SRT can improve patient outcomes. We want to increase patient access to these cutting-edge therapies. RTsafe’s technology should make it easier for smaller and non-academic care centers to confidently implement Elekta’s HDRS solution, allowing more patients access to precision radiation medicine.” 

RTsafe has developed high-fidelity Reference PseudoPatient™ 3D printed head phantoms true-to-life reproduction of human anatomy, enabling customers to perform quality assurance end-to-end testing of their SRS/SRT systems with a high level of precision and accuracy. The whole service instills confidence in SRS clinical use, achieving optimal treatment efficiency and patient safety.

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com 
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.